Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Marcin Jan Szumowski Ph.D. | Co-Founder, CEO & President of Management Board | -- | -- | -- |
| Mr. Slawomir Piotr Broniarek | CFO & Member of the Management Board | -- | -- | -- |
| Dr. Zbigniew Zaslona | Chief Scientific Officer & Member of Management Board | -- | -- | -- |
| Ms. Agnieszka Rajczuk-Szczepanska | Member of Management Board & HR Director | -- | -- | -- |
| Dr. Adam Golebiowski Ph.D. | Co-Founder & VP of Research Chemistry | -- | -- | -- |
| Mr. Jacek Olczak Ph.D. | Co-Founder & Head of Medicinal Chemistry | -- | -- | -- |
| Dr. Piotr Iwanowski | Chief Medical Officer & Member of Management Board | -- | -- | -- |
| Ms. Magdalena Tyszkiewicz | Head of CMC | -- | -- | -- |
| Ms. Marta Borkowska | Director of the Management Board Office | -- | -- | -- |
Molecure S.A.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 105
Description
Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of cancer; USP7, USP21, and YKL-40 for the treatment of cancer; and Deubiquitinase program. The company was formerly known as OncoArendi Therapeutics S.A. and changed its name to Molecure S.A. in March 2022. Molecure S.A. was founded in 2012 and is headquartered in Warsaw, Poland.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available